SDM25N is a Dengue virus (DENV) inhibitor with an EC50 of 1.9 µM. SDM25N inhibits DENV in a cell type-specific manner. SDM25N restricts genomic RNA replication by targeting the viral NS4B protein. SDM25N can be used for DENV infection research.

SDH-IN-37 (Compound A37) is a potent SDH inhibitor, with an IC50 value of 0.0263 μM. SDH-IN-37 is also an antifungal agent. SDH-IN-37 demonstrates antifungal activities against Rhizoctonia solani, S. sclerotiorum and F. graminearum, with EC50 values of 0.0144, 0.882 and 1.99 μg/mL, respectively.

SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation.

SCH-720881 is the active metabolite of Rolapitant. Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model.

SCH-602539 is a selective PAR-1 antagonist. SCH-602539 inhibits platelet aggregation in response to PAR-1-selective high-affinity thrombin receptor agonist peptide. SCH-602539 exhibits synergistic antithrombotic effects when used in combination with Cangrelor.

SCH 47896 is a phenolic derivative of SCH39370, a potent specific inhibitor of metalloendopeptidase (NEP). SCH 47896 can be used for the research of cardiovascular disease, such as hypertension.

SCH 2047069 (MK-8267) is an orally active kinesin spindle protein (KSP) inhibitor (Kd: 0.5 nM) that can cross the blood-brain barrier. SCH 2047069 exhibits an IC50 value of ≤ 5 nM against the KSP ATPase. SCH 2047069 exhibits broad-spectrum antitumor activity. SCH 2047069 can induce mitotic arrest and apoptosis in tumor cells. SCH 2047069 can be used in the research of tumors such as ovarian cancer, colon cancer, glioblastoma, and lymphoma.

SBP-1750 is an orally active ULK inhibitor and an ATG13 degrader. SBP-1750 strongly inhibits ULK1/2 activity, with IC50 values of 8 and 50 nM, respectively. SBP-1750 induces ATG13 degradation, with an EC50 value of 114 nM. SBP-1750 can inhibit autophagy in cancer cells and induce cell death. SBP-1750 can be used in cancer research, such as for pancreatic cancer.

SB-699551 free base is a selective and brain penetrant 5-HT5A receptor antagonist with a pKi of 8.2 nM. SB-699551 free base shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 free base disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 free base can be used for the research of anxiety, breast cancer, and Alzheimer's disease.

SB-587094 is a MetAP-2 inhibitor. SB-587094 inhibits cobalt- and manganese-containing hMetAP2. SB-587094 inhibits endothelial cell proliferation. SB-587094 is applicable to cancer-related research.

SB5-171 is a covalent PfCLK3 inhibitor with IC50 values of 10-12 nM. SB5-171shows antiparasitic activity. SB5-171 can be used for the research of malaria.

SB2960 is a receptor for activated protein C kinase 1 (RACK1) binder with a human KD of 5.65 μM. SB2960 can promote stress granule (SG) formation and exhibit potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. SB2960 increases the thermal stability of RACK1 and reduces SARS-CoV-2 N protein levels. SB2960 enhances type I interferon (IFN-β) expression and inhibits RIG-I, ISG56, and RANTES expression. SB2960 can be used for the research of virus infection.

SB1578 (CT-1578) is a selective JAK2 and FLT3 inhibitor with an IC50 of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis.

SB 247464 is an orally active nonpeptidyl ligand. SB 247464 can selectively activate the murine granulocyte colony-stimulating factor (G-CSF) signaling pathway and mimic the biological functions of G-CSF. SB 247464 can be used for the study of neutropenia and other diseases.

Satranidazole is an orally effective insecticide and antimicrobial agent with high electron affinity. Satranidazole forms reduced nitro intermediates, which interact with DNA, causing helix instability, strand breakage and release of thymidine derivatives. Satranidazole exhibits antitrichomonal activity against Trichomonas vaginalis and Trichomonas foetus, and antiamoebic activity in rodent models of hepatic amoebiasis and caecal amoebiasis. Satranidazole inhibits the replication of bacteriophage φX174 DNA. Satranidazole can be used in research related to caecal amoebiasis, trichomoniasis and anaerobic bacterial infections.

SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC50 of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC50 s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC50 : 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research.

SAR113945 (compound 1) is a highly potent IKK-β inhibitor with an IC50 of 0.4 nM. SAR113945 is used for research on inflammatory and cancerous diseases.

Sameridine (NIH-10908 free base) is a weak partial agonist of the μ-opioid receptor. Sameridine shows local anesthetic and analgesic properties. Sameridine has minimal respiratory depression at low doses, but can suppress ventilatory response at high doses. Sameridine can be used for the study of analgesic effect.

Salanersen is an antisense oligonucleotide targeted to survival motor neuron 2 (SMN2). It is used for the study of spinal muscular atrophy (SMA).

S-Adenosyl-L-ethionine is S-Adenosyl-L-methione analog. S-Adenosyl-L-ethionine is able to replace S-Adenosyl-L-methione during HydG catalysis. HydG can utilize S-Adenosyl-L-ethionine as an effective alternative cosubstrate to S-Adenosyl-L-methione under normal enzymatic turnover conditions, producing the Ω intermediate and allowing efficient catalytic turnover of substrate L-tyrosine.

S-8666 is an orally active uricosuric antihypertensive diuretic. The S-8666 has both S-(-)- and R-(+)-isomers. The diuretic and sodium-excretion activities of it are entirely dominated by the S-(-)-isomer, while the R-(+)-isomer shows no significant activity. S-8666 relies on the organic acid transport system to be secreted through the proximal tubule. S-8666 exhibits a clear uric acid excretion-promoting activity and diuretic effect in various species (such as rats and chimpanzees).

S1R agonist 3 is a potent and selective sigma-1 receptor (S1R) agonist with a Ki of 1.5 nM. S1R agonist 3 reduces hyperlocomotion in wfs1abKO zebrafish larvae without affecting locomotion in wildtype wfs1abWT zebrafish larvae. S1R agonist 3 reverses Aβ25-35-induced learning and memory impairments. S1R ligand 1 can be used for the research of Alzheimer’s disease.

S1PR1/S1PR5 agonist-1 (Compound 19) is an orally active S1PR1 and S1PR5 agonist with EC50 values of 40.0 and 22.9 nM, respectively. S1PR1/S1PR5 agonist-1 binds to key residues of S1PR1 to mediate agonistic activity. S1PR1/S1PR5 agonist-1 alleviates colitis pathological changes in DSS-induced mouse models and exerts minimal effects on mouse heart rate. S1PR1/S1PR5 agonist-1 can be used for the research of inflammatory bowel disease.

S1PR1 agonist 3 (Compound Y18) is a highly selective S1PR1 receptor agonist (EC50=0.98 nM). S1PR1 agonist 3 is promising for research of autoimmune diseases such as multiple sclerosis and ulcerative colitis.

RX-RA-69 is an orally active platelet phosphodiesterase (PDE) inhibitor with a IC50 of 1 nM. RX-RA-69 elevates cAMP levels in platelets, exerts anti-aggregatory effects, and inhibits the formation of coronary platelet thrombi. RX-RA-69 exhibits anti-metastatic activity in a mouse Lewis lung cancer model. RX-RA-69 can be used in research related to coronary platelet thrombi and Lewis lung cancer.

RU 56279 is an androgen receptor (AR) antagonist with strong and systemic anti-androgenic activity. RU 56279 is also a common, potent and long-lasting anti-androgen metabolite of RU 56187 and RU 58841 in vivo. RU 56279 can be used as an AR ligand to construct an AR-targeted prodrug system for the study of AR-positive tumor cells.

RSK4-IN-2 (compound 16o) is a potent, orally active RSK4 inhibitor with an IC50 of 17 nM. RSK4-IN-2 suppresses esophageal squamous cell carcinoma (ESCC) cell growth and invasion, by inhibiting phosphorylation of RSK4 downstream targets. RSK4-IN-2 inhibits tumor growth and metastasis in ESCC mouse models. RSK4-IN-2 can be used for ESCC research.

RPR-200765A methanesulfonate is an orally active p38 MAPK inhibitor with an IC50 of 0.050 μM. RPR-200765A methanesulfonate shows weak activity against Lck, and exhibits no significant activity against ERK, ZAP70 or SYK. It inhibits the production of TNFα and can be used in the research of inflammatory diseases.

Rosuvastatin TMBA (ZD 4522 TMBA) is a drug impurity.

RORγt inverse agonist 36 (S configuration of Compound 16) is a RORγt inverse agonist. RORγt inverse agonist 36 can be used for the research of inflammation and immunology.